Senisca Ltd raises £3.7m seed money
The proceeds of Senisca’s latest funding round led by Lifespan Vision Venture will support the preclinical development of the company’s...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Jazz Pharmaceuticals licences KRAS blocker from Redx Pharma
Under the term of the agreement, Redx Pharma plc (Alderley Park, UK) is to receive US$10m upfront and up to US$870m in milestone payments. Redx is...
Novo Nordisk to acquire Cardior Pharmaceuticals
The take-over agreement includes Cardior’s lead compound CDR132L, currently in Phase II clinical development for the treatment of heart failure....
Solar Foods starts Factory01
Following market authorisation in Singapore two years ago, the Finnish company Solar Foods Oy and the Japanese food giant Ajinomoto Group want to...
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Under the agreement with Lonza AG, NeuroSense Therapeutics Ltd will advance early diagnosis and treatment in the neurodegeneration field. Last...
Spexis sells antibiotics programme to Basilea
Spexis AG (Alschwil) has entered into an asset purchase agreement with Basilea Pharmaceutica Ltd. Under the agreement Basilea will acquire a...